FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2063110337> ?p ?o ?g. }

• W2063110337 endingPage "1492" @default.
• W2063110337 startingPage "1485" @default.
• W2063110337 abstract "<b>Background:</b> Interferon beta (IFNβ) administered subcutaneously is immunogenic in some patients with multiple sclerosis (MS) and leads to the development of neutralizing antibodies (NAbs). Considerable evidence has accumulated that NAbs diminish or abolish IFNβ bioactivity, but there is less evidence that NAbs impact clinical efficacy of the drug. <b>Methods:</b> Because a robust effect of IFNβ is a decrease in enhancing lesions on brain MRI scans, the Betaseron Copaxone in Multiple Sclerosis With Triple-Dose Gadolinium and 3-Tesla MRI Endpoints (BECOME) study, a head-to-head study of IFNβ-1b vs glatiramer acetate with a primary endpoint of enhancing lesions on MRI, provided an excellent opportunity to determine the effect of NAbs on MRI activity. We measured NAbs and IFNβ bioactivity by myxovirus resistance protein A gene expression and identified 2 groups of patients: one labeled “bioactivity preserved,” with absent NAbs and robust IFNβ bioactivity (n = 8), and the other labeled “bioactivity lost,” with high levels of NAbs and diminished bioactivity (n = 7). The development of enhancing lesions in the groups was then compared. <b>Results:</b> The incidence of NAbs and effect of NAbs on bioactivity were consistent with previous studies. We analyzed MRI outcomes in patients with NAbs at levels high enough to abolish bioactivity relative to patients without NAbs. For the preserved bioactivity group, the enhancing lesion/scan ratio decreased from 7.6 in the pretreatment period to 2.6 in the posttreatment period, a 66% decrease. For the lost bioactivity group, the decrease was 8.5 to 5.8, only a 32% decrease. Thus, lost bioactivity from high levels of NAbs resulted in reduced therapeutic efficacy of IFNβ as manifested by diminished reductions in enhancing lesions on MRI. <b>Conclusions:</b> High levels of anti–interferon beta (IFNβ) antibodies, which result in diminished bioactivity, are correlated with reduced therapeutic efficacy of IFNβ." @default.
• W2063110337 created "2016-06-24" @default.
• W2063110337 creator A5046173973 @default.
• W2063110337 creator A5062454377 @default.
• W2063110337 creator A5088163706 @default.
• W2063110337 creator A5089629920 @default.
• W2063110337 date "2009-11-02" @default.
• W2063110337 modified "2023-09-26" @default.
• W2063110337 title "Effect of anti-IFN antibodies on MRI lesions of MS patients in the BECOME study" @default.
• W2063110337 cites W1966221405 @default.
• W2063110337 cites W1973550674 @default.
• W2063110337 cites W1975995030 @default.
• W2063110337 cites W1977759475 @default.
• W2063110337 cites W1980076164 @default.
• W2063110337 cites W1985224319 @default.
• W2063110337 cites W1987745782 @default.
• W2063110337 cites W1993417921 @default.
• W2063110337 cites W2004996759 @default.
• W2063110337 cites W2015730831 @default.
• W2063110337 cites W2016173904 @default.
• W2063110337 cites W2020952837 @default.
• W2063110337 cites W2023385152 @default.
• W2063110337 cites W2038240352 @default.
• W2063110337 cites W2044346839 @default.
• W2063110337 cites W2047575804 @default.
• W2063110337 cites W2054843986 @default.
• W2063110337 cites W2073827812 @default.
• W2063110337 cites W2079043571 @default.
• W2063110337 cites W2106379179 @default.
• W2063110337 cites W2109939012 @default.
• W2063110337 cites W2120389810 @default.
• W2063110337 cites W2125919119 @default.
• W2063110337 cites W2129012981 @default.
• W2063110337 cites W2131709112 @default.
• W2063110337 cites W2137782187 @default.
• W2063110337 cites W2140480207 @default.
• W2063110337 cites W2141487451 @default.
• W2063110337 cites W2161552221 @default.
• W2063110337 cites W2164542304 @default.
• W2063110337 cites W2171104471 @default.
• W2063110337 cites W2039922812 @default.
• W2063110337 doi "https://doi.org/10.1212/wnl.0b013e3181bf9919" @default.
• W2063110337 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19884576" @default.
• W2063110337 hasPublicationYear "2009" @default.
• W2063110337 type Work @default.
• W2063110337 sameAs 2063110337 @default.
• W2063110337 citedByCount "36" @default.
• W2063110337 countsByYear W20631103372012 @default.
• W2063110337 countsByYear W20631103372013 @default.
• W2063110337 countsByYear W20631103372014 @default.
• W2063110337 countsByYear W20631103372015 @default.
• W2063110337 countsByYear W20631103372017 @default.
• W2063110337 countsByYear W20631103372018 @default.
• W2063110337 countsByYear W20631103372020 @default.
• W2063110337 countsByYear W20631103372021 @default.
• W2063110337 countsByYear W20631103372022 @default.
• W2063110337 countsByYear W20631103372023 @default.
• W2063110337 crossrefType "journal-article" @default.
• W2063110337 hasAuthorship W2063110337A5046173973 @default.
• W2063110337 hasAuthorship W2063110337A5062454377 @default.
• W2063110337 hasAuthorship W2063110337A5088163706 @default.
• W2063110337 hasAuthorship W2063110337A5089629920 @default.
• W2063110337 hasConcept C126322002 @default.
• W2063110337 hasConcept C126838900 @default.
• W2063110337 hasConcept C142724271 @default.
• W2063110337 hasConcept C143409427 @default.
• W2063110337 hasConcept C159654299 @default.
• W2063110337 hasConcept C203014093 @default.
• W2063110337 hasConcept C2778577042 @default.
• W2063110337 hasConcept C2780640218 @default.
• W2063110337 hasConcept C2781156865 @default.
• W2063110337 hasConcept C71924100 @default.
• W2063110337 hasConcept C98274493 @default.
• W2063110337 hasConceptScore W2063110337C126322002 @default.
• W2063110337 hasConceptScore W2063110337C126838900 @default.
• W2063110337 hasConceptScore W2063110337C142724271 @default.
• W2063110337 hasConceptScore W2063110337C143409427 @default.
• W2063110337 hasConceptScore W2063110337C159654299 @default.
• W2063110337 hasConceptScore W2063110337C203014093 @default.
• W2063110337 hasConceptScore W2063110337C2778577042 @default.
• W2063110337 hasConceptScore W2063110337C2780640218 @default.
• W2063110337 hasConceptScore W2063110337C2781156865 @default.
• W2063110337 hasConceptScore W2063110337C71924100 @default.
• W2063110337 hasConceptScore W2063110337C98274493 @default.
• W2063110337 hasIssue "18" @default.
• W2063110337 hasLocation W20631103371 @default.
• W2063110337 hasLocation W20631103372 @default.
• W2063110337 hasOpenAccess W2063110337 @default.
• W2063110337 hasPrimaryLocation W20631103371 @default.
• W2063110337 hasRelatedWork W102576517 @default.
• W2063110337 hasRelatedWork W1975806676 @default.
• W2063110337 hasRelatedWork W2062532180 @default.
• W2063110337 hasRelatedWork W2133936961 @default.
• W2063110337 hasRelatedWork W2143205494 @default.
• W2063110337 hasRelatedWork W2147912507 @default.
• W2063110337 hasRelatedWork W2395410554 @default.
• W2063110337 hasRelatedWork W2396047537 @default.
• W2063110337 hasRelatedWork W2775342387 @default.

• next